STUDY PROTOCOL article
Front. Psychiatry
Sec. Addictive Disorders
Volume 16 - 2025 | doi: 10.3389/fpsyt.2025.1576277
This article is part of the Research TopicBody Sensor Networks, Mobile Application Monitoring and Prescription Digital Therapeutics for Personalized Mental Health and Substance Use Management and TreatmentView all articles
Digitally delivered contingency management during methadone treatment for people with co-occurring cocaine and opioid use: a protocol for a randomized controlled trial
Provisionally accepted
- Friends Research Institute, Inc., Baltimore, United States
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Background. People in treatment for opioid use disorder (OUD) who also use cocaine are at heightened risk of early treatment discontinuation and poor outcomes. Digital therapeutics utilized within OUD treatment have the potential to impact public health by improving the evidence-based intervention delivery. Contingency management (CM) is an evidence-based intervention to reduce substance use, including cocaine. This article details a randomized controlled trial protocol that tests a digitally-delivered CM intervention for adult patients with cooccurring cocaine and opioid use entering methadone treatment.Methods. This study will enroll 240 individuals within two weeks of beginning a new treatment episode at one of four participating opioid treatment programs (OTPs) in Baltimore, Maryland. Eligible adults must report past 30-day cocaine and opioid use at intake. Participants are randomized to receive either treatment as usual (TAU) or TAU plus the DynamiCare Contingency Management (DCM) app. The DCM app facilitates the provision of small monetary incentives for picking up methadone doses, completing cognitive behavioral therapy educational modules, and testing negative for cocaine or opioids on randomly-scheduled self-administered and validated oral fluid drug tests. The primary outcome is retention in methadone treatment. Participants are assessed at baseline, 3-, 6-and 12-months on measures including substance use and quality of life, and qualitative interviews are conducted with a subset of DCM-arm participants to assess acceptability and utility of the intervention. This trial was registered in the National Clinical Trials database on February 23, 2023, according to NIH policy (https://clinicaltrials.gov/study/NCT05766631).Discussion. This project will inform the ancillary content of methadone maintenance treatment for the many patients with substance use disorders that extend beyond opioids, specifically for those who use cocaine. The study's design will provide scientifically valid information about the effectiveness of digitally delivered CM, while app usage data and qualitative data from participants will be a rich resource for interpreting outcome results. CM is the only known evidence-based treatment for stimulant disorder, and digital delivery could solve many of the practical issues that have hampered widespread adoption of CM. Thus, the study could have both an important scientific and public health impact.
Keywords: Opioid use disorder, Cocaine, Contingency Management, digital therapeutic, Methadone
Received: 13 Feb 2025; Accepted: 16 Jun 2025.
Copyright: © 2025 Alexander, Sharma, Fletcher, Smith, Huddleston, Gryczynski and Stitzer. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Karen Alexander, Friends Research Institute, Inc., Baltimore, United States
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.